Why did diluted EPS grow 10.9% when net income grew only 0.6%?

Share repurchases reduced the diluted share count from 249.4 million to 226.7 million, about 9%. Because EPS equals net income divided by shares, the lower share count lifted EPS well above the modest growth in net income. The company spent $1.571 billion on buybacks during the quarter.

Are the Medicaid supplemental program gains a durable source of earnings?

Not clearly. The release says these recognitions were not included in the initial 2026 guidance and helped offset weak volumes in the quarter. Such payments depend on state programs and approvals, and the filing flags possible reductions or changes to Medicaid supplemental and state directed payments as a risk. Investors should treat this as potentially non-recurring until more visibility is provided.

Is the company's guidance at risk given the soft start to 2026?

The company reaffirmed its full-year guidance rather than raising or lowering it. Q1 Adjusted EBITDA of $3.802 billion is about 24% of the midpoint of the $15.55–16.45 billion range, and the volume shortfall was partly masked by supplemental payments. The guidance assumes a mostly stable operating environment and excludes future approvals of certain Medicaid supplemental payments, so the outcome depends on volume recovery and continued program approvals.

How is HCA's balance sheet and debt position changing?

Total debt was $48.0 billion at March 31, 2026. Short-term borrowings and debt due within one year rose to $8.5 billion from $4.9 billion at year-end, while long-term debt fell to $39.5 billion. Stockholders' deficit attributable to HCA widened to $(6.3) billion. Liquidity includes $940 million in cash and $4.336 billion of available credit facility capacity. Investors should monitor refinancing of the near-term maturities.

Is the dividend secure?

The $0.78 quarterly dividend is payable June 30, 2026, to holders of record on June 16, 2026. The company states it expects to fund dividends from cash balances and future operating cash flow, which grew 22% this quarter. Dividend payments remain at the discretion of the board. Dividends paid in Q1 were $183 million, versus $1.571 billion spent on buybacks, indicating capital return is weighted toward repurchases.

HCA 8-K: Earnings & Results & Regulation FD

01—Abstract

Summary

Summary of the 8-K filed April 24, 2026. Cited figures are marked; the original filing is the authoritative source.

HCA Healthcare reported first quarter 2026 results that were mixed beneath a headline EPS gain.

Revenue rose 4.3% to $19.109 billion^a, and diluted EPS increased 10.9% to $7.15, but that EPS growth was driven largely by a sharply lower share count (226.7 million diluted shares versus 249.4 million a year earlier, reflecting about $1.57 billion of buybacks). Net income attributable to HCA grew only 0.6% to $1.620 billion, and Adjusted EBITDA rose just 1.9% to $3.802 billion, with the Adjusted EBITDA margin contracting from 20.4% to 19.9%. Operating volumes were soft.

Same facility admissions rose 0.9%^b and equivalent admissions rose 1.3%, but inpatient surgeries fell 0.3%, outpatient surgeries fell 1.7%, and the company did not see its typical seasonal first-quarter volume increase. Respiratory-related admissions fell 42% year over year, and a January winter storm also weighed on volumes. Management said these headwinds were mostly offset by recognition of Medicaid supplemental program revenue that was not in its initial 2026 guidance.

Pricing was the main growth driver, with same facility revenue per equivalent admission up 3.1%^c. Salaries and benefits and other operating expenses grew faster than revenue, which compressed margins. Cash generation and capital return were strong.

Operating cash flow rose 22.0% to $2.014 billion^d, and the company repurchased $1.571 billion of stock. Total debt stood at $48.0 billion, with $8.5 billion of short-term borrowings and debt due within one year, up from $4.9 billion at year-end. The company reaffirmed its 2026 guidance of $76.5–80.0 billion in revenue, $15.55–16.45 billion in Adjusted EBITDA, and $29.10–31.50 in diluted EPS, and declared a quarterly dividend of $0.78 per share payable June 30, 2026.

02—Key points

Key Highlights

Revenue increased 4.3% to $19.109 billion, while net income attributable to HCA rose only 0.6% to $1.620 billion.
Diluted EPS rose 10.9% to $7.15, but the gain was driven mainly by a 9% reduction in diluted share count (226.7M vs. 249.4M) from buybacks.
Adjusted EBITDA grew 1.9% to $3.802 billion, and the Adjusted EBITDA margin declined from 20.4% to 19.9%.
Same facility admissions rose 0.9% and equivalent admissions rose 1.3%, but outpatient surgeries fell 1.7% and respiratory-related admissions fell 42%.
Revenue per equivalent admission rose 3.1% on a same facility basis, and Medicaid supplemental program recognition offset volume weakness.
Operating cash flow rose 22.0% to $2.014 billion, and the company repurchased $1.571 billion of stock, leaving $9.179 billion of authorization remaining.
Guidance for 2026 was reaffirmed (revenue $76.5–80.0B, Adjusted EBITDA $15.55–16.45B, diluted EPS $29.10–31.50), and a $0.78 quarterly dividend was declared.

03—Questions

Frequently Asked Questions

Why did diluted EPS grow 10.9% when net income grew only 0.6%?
Share repurchases reduced the diluted share count from 249.4 million to 226.7 million, about 9%. Because EPS equals net income divided by shares, the lower share count lifted EPS well above the modest growth in net income. The company spent $1.571 billion on buybacks during the quarter.
Are the Medicaid supplemental program gains a durable source of earnings?
Not clearly. The release says these recognitions were not included in the initial 2026 guidance and helped offset weak volumes in the quarter. Such payments depend on state programs and approvals, and the filing flags possible reductions or changes to Medicaid supplemental and state directed payments as a risk. Investors should treat this as potentially non-recurring until more visibility is provided.
Is the company's guidance at risk given the soft start to 2026?
The company reaffirmed its full-year guidance rather than raising or lowering it. Q1 Adjusted EBITDA of $3.802 billion is about 24% of the midpoint of the $15.55–16.45 billion range, and the volume shortfall was partly masked by supplemental payments. The guidance assumes a mostly stable operating environment and excludes future approvals of certain Medicaid supplemental payments, so the outcome depends on volume recovery and continued program approvals.
How is HCA's balance sheet and debt position changing?
Total debt was $48.0 billion at March 31, 2026. Short-term borrowings and debt due within one year rose to $8.5 billion from $4.9 billion at year-end, while long-term debt fell to $39.5 billion. Stockholders' deficit attributable to HCA widened to $(6.3) billion. Liquidity includes $940 million in cash and $4.336 billion of available credit facility capacity. Investors should monitor refinancing of the near-term maturities.
Is the dividend secure?
The $0.78 quarterly dividend is payable June 30, 2026, to holders of record on June 16, 2026. The company states it expects to fund dividends from cash balances and future operating cash flow, which grew 22% this quarter. Dividend payments remain at the discretion of the board. Dividends paid in Q1 were $183 million, versus $1.571 billion spent on buybacks, indicating capital return is weighted toward repurchases.

04—Continue

← View all 8-K filings